ADMETatlas — Peptide ADMET Evidence Atlas

ADMETatlas — Peptide ADMET Evidence Atlas

Evidence entries

7records·53peptides

Showing reference-linked Volume of distribution evidence with reported value, assay context, interpretation role, and reference access kept separate.

Assay context

Evidence role

#	Endpoint	Peptide		Assay context	Evidence role	Reference
1	Volume of distribution Distribution / Barrier	ATLPC0015302	Observation Given that linaclotide plasma concentrations following recommended oral doses are not measurable, linaclotide is not expected to be distributed to tissues to any clinically relevant extent.	DailyMed SPL 12.3 Pharmacokinetics label extractionplasmahumanoral	Reported	Open
2	Volume of distribution Distribution / Barrier	ATLPC0019952	Observation Given that plecanatide concentrations following clinically relevant oral doses were not measurable, plecanatide is expected to be minimally distributed in tissues.	DailyMed SPL 12.3 Pharmacokinetics label extractionhumanoral	Reported	Open
3	Volume of distribution Distribution / Barrier	ATLPC0006669	Observation Total plasma clearance (CL T ), elimination half-life (t 1/2 ), and volume of distribution at steady-state (V ss ) in patients with cSSSI were similar to those in patients with S. aureus bacteremia.	DailyMed SPL 12.3 Pharmacokinetics label extractionplasmahuman	Reported	Open
4	Volume of distribution Distribution / Barrier	ATLPC0006669	Observation The mean steady-state systemic exposure (AUC), t 1/2 , and V ss increased with decreasing renal function, although the mean AUC for patients with CL CR 30–80 mL/min was not markedly different from the mean AUC for patients with normal renal function.	DailyMed SPL 12.3 Pharmacokinetics label extractionhuman	Reported	Open
5	Volume of distribution Distribution / Barrier	ATLPC0025050	> 1 L/kg	DailyMed SPL 12.3 Pharmacokinetics label extractionhumansubcutaneous	Reported	Open
6	Volume of distribution Distribution / Barrier	ATLPC0025050	> 1,000 L	DailyMed SPL 12.3 Pharmacokinetics label extractionhumansubcutaneous	Reported	Open
7	Volume of distribution Distribution / Barrier	ATLPC0020556	Observation In a study performed in 4 subjects with end-stage renal disease (creatinine clearance < 5 mL/min), an intravenous infusion of 3.5 mg/kg of cyclosporine over 4 hours administered at the end of a hemodialysis session resulted in a mean volume of distribution (Vdss) of 3.49 L/kg and systemic clearance (CL) of 0.369 L/hr/kg.	DailyMed SPL 12.3 Pharmacokinetics label extractionhumanintravenous	Reported	Open

1–7 / 7